Immunosuppression medication and cardiac function improvement treatments might prevent Takayasu arteritis patients with aortitis from receiving cardiac surgery
Chin Med J (Engl)
.
2020 Oct 14;134(5):625-627.
doi: 10.1097/CM9.0000000000001160.
Authors
Xiao-Min Dai
1
,
Yu-Jiao Wang
1
,
Zhen-Chun Zhang
2
,
Cheng-De Yang
3
,
Rui Wu
4
,
Zhen-Yuan Zhou
5
,
Xiao-Xiang Chen
5
,
Xiao-Ning Sun
6
,
Chun-Sheng Wang
6
,
Li-Li Ma
1
,
Lin-Di Jiang
1
7
;
and the East China Takayasu Arteritis (ECTA) Collaboration Group
Affiliations
1
Department of Rheumatology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
2
Department of Rheumatology, Linyi People's Hospital, Linyi, Shandong 276003, China.
3
Department of Rheumatology, Ruijin Hospital, Shanghai Jiaotong University Medical College, Shanghai 200025, China.
4
Department of Rheumatology, The First Affiliated Hospital, Nanchang University, Nanchang, Jiangxi 330006, China.
5
Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University Medical College, Shanghai 200001, China.
6
Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
7
Evidence-based Medicine Centre, Fudan University, Shanghai 200032, China.
PMID:
33060369
PMCID:
PMC7929491
DOI:
10.1097/CM9.0000000000001160
No abstract available
MeSH terms
Aorta
Aortitis*
Cardiac Surgical Procedures*
Humans
Immunosuppression Therapy
Takayasu Arteritis* / drug therapy